Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andolast

Drug Profile

Andolast

Alternative Names: CR 2039; Diazolast

Latest Information Update: 04 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Antiallergics; Antiasthmatics; Benzamides; Small molecules; Tetrazoles
  • Mechanism of Action Calcium-activated potassium channel openers; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Aug 2015 Phase-III development is ongoing in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in Italy
  • 23 Oct 2014 Phase III development is ongoing in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top